![Frontiers | Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy | Oncology Frontiers | Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy | Oncology](https://www.frontiersin.org/files/Articles/52319/fonc-03-00155-HTML/image_m/fonc-03-00155-g001.jpg)
Frontiers | Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy | Oncology
![The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology](https://cdn.amegroups.cn/journals/pbpc/files/journals/1/articles/181/public/181-1288-1-PB.jpg)
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology
![Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas – A retrospective tumor marker prognostic study - ScienceDirect Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas – A retrospective tumor marker prognostic study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1743919113010789-gr1.jpg)
Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas – A retrospective tumor marker prognostic study - ScienceDirect
![Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine | British Journal of Cancer Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsj.bjc.6601263/MediaObjects/41416_2003_Article_BF6601263_Fig1_HTML.jpg)
Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine | British Journal of Cancer
![Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers | Semantic Scholar Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/bf27a8f33dc1177ab0c7cf3c2adec21f5727b20d/3-Table1-1.png)
Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers | Semantic Scholar
![Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom Score - HPB Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom Score - HPB](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2039490123/2053093477/gr1.jpg)
Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom Score - HPB
![CA 19-9 level in different T stages, grades, depth of invasion, and in... | Download Scientific Diagram CA 19-9 level in different T stages, grades, depth of invasion, and in... | Download Scientific Diagram](https://www.researchgate.net/publication/225044947/figure/tbl1/AS:202694657613824@1425337580006/CA-19-9-level-in-different-T-stages-grades-depth-of-invasion-and-in-metastatic.png)
CA 19-9 level in different T stages, grades, depth of invasion, and in... | Download Scientific Diagram
![CA19–9 decrease and survival according to platelet level in patients with advanced pancreatic cancer | BMC Cancer | Full Text CA19–9 decrease and survival according to platelet level in patients with advanced pancreatic cancer | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-019-6078-2/MediaObjects/12885_2019_6078_Fig1_HTML.png)
CA19–9 decrease and survival according to platelet level in patients with advanced pancreatic cancer | BMC Cancer | Full Text
![Cureus | Is There a Role of Elevated CA 19-9 Levels in the Evaluation of Clinical Characteristics of Mature Cystic Ovarian Teratomas? A Systematic Review and Meta-analysis Cureus | Is There a Role of Elevated CA 19-9 Levels in the Evaluation of Clinical Characteristics of Mature Cystic Ovarian Teratomas? A Systematic Review and Meta-analysis](https://assets.cureus.com/uploads/figure/file/84959/lightbox_6c2454701b0811eaa782efc044130466-Figure-3---24562.png)
Cureus | Is There a Role of Elevated CA 19-9 Levels in the Evaluation of Clinical Characteristics of Mature Cystic Ovarian Teratomas? A Systematic Review and Meta-analysis
![CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2001025641/2003896921/gr1.gif)
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology
![Clinical Value of Serum CEA, CA 19-9, CA 242 and AFP in Diagnosis of Gastrointestinal Tract Cancers - SciAlert Responsive Version Clinical Value of Serum CEA, CA 19-9, CA 242 and AFP in Diagnosis of Gastrointestinal Tract Cancers - SciAlert Responsive Version](https://docsdrive.com/images/academicjournals/ijcr/2006/tab3-2k6-50-56.gif)
Clinical Value of Serum CEA, CA 19-9, CA 242 and AFP in Diagnosis of Gastrointestinal Tract Cancers - SciAlert Responsive Version
![Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas – A retrospective tumor marker prognostic study - ScienceDirect Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas – A retrospective tumor marker prognostic study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1743919113010789-gr3.jpg)
Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas – A retrospective tumor marker prognostic study - ScienceDirect
![SciELO - Brasil - Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer Further evidence of the prognostic role of pretreatment levels of CA 19-9 SciELO - Brasil - Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer Further evidence of the prognostic role of pretreatment levels of CA 19-9](https://minio.scielo.br/documentstore/1806-9282/g8Lp4xbbWB78G55CbTG7YhQ/348deb905074e13dece8857563da368a3a77eebd.gif)
SciELO - Brasil - Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer Further evidence of the prognostic role of pretreatment levels of CA 19-9
![Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies](http://www.tropicalgastro.com/uploads/Untitlemscd-31.jpg)
Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies
![The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology](https://cdn.amegroups.cn/journals/pbpc/files/journals/1/articles/181/public/181-1293-1-PB.jpg)
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology
![Dynamic change of serum CA19–9 levels in benign and malignant patients with obstructive jaundice after biliary drainage and new correction formulas | BMC Cancer | Full Text Dynamic change of serum CA19–9 levels in benign and malignant patients with obstructive jaundice after biliary drainage and new correction formulas | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-021-08204-w/MediaObjects/12885_2021_8204_Fig3_HTML.png)
Dynamic change of serum CA19–9 levels in benign and malignant patients with obstructive jaundice after biliary drainage and new correction formulas | BMC Cancer | Full Text
![PDF] Assessing Prognosis in Metastatic Pancreatic Cancer by the Serum Tumor Marker CA 19-9: Pretreatment Levels or Kinetics during Chemotherapy? | Semantic Scholar PDF] Assessing Prognosis in Metastatic Pancreatic Cancer by the Serum Tumor Marker CA 19-9: Pretreatment Levels or Kinetics during Chemotherapy? | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/f7bb4eb6de25f6ecb9323cbef8061896f020a0da/2-Table1-1.png)
PDF] Assessing Prognosis in Metastatic Pancreatic Cancer by the Serum Tumor Marker CA 19-9: Pretreatment Levels or Kinetics during Chemotherapy? | Semantic Scholar
![Frontiers | Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy | Oncology Frontiers | Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy | Oncology](https://www.frontiersin.org/files/Articles/52319/fonc-03-00155-HTML/image_m/fonc-03-00155-g002.jpg)